prikaz prve stranice dokumenta Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients
  Download
PDF 363.43 KB
Scientific paper - Original scientific paper
Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 105 (2021); 110016. https://doi.org/10.1016/j.pnpbp.2020.110016
Dvojković, Anja; Nikolac Perković, Matea; Šagud, Marina; Nedić Erjavec, Gordana; Mihaljević Peleš, Alma; Švob Štrac, Dubravka; Vuksan Ćusa, Bjanka; Tudor, Lucija; Kušević, Zorana; Konjevod, Marcela; Živković, Maja; Jevtović, Saša; Pivac, Nela

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Dvojković, A., Nikolac Perković, M., Šagud, M., Nedić Erjavec, G., Mihaljević Peleš, A., Švob Štrac, D. ... Pivac, N. (2021). Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 105.. doi: 10.1016/j.pnpbp.2020.110016

Dvojković, Anja, et al. "Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients." Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 105, 2021. https://doi.org/10.1016/j.pnpbp.2020.110016

Dvojković, Anja, Matea Nikolac Perković, Marina Šagud, Gordana Nedić Erjavec, Alma Mihaljević Peleš, Dubravka Švob Štrac, Bjanka Vuksan Ćusa, et al. "Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients." Progress in Neuro-Psychopharmacology and Biological Psychiatry 105 (2021). https://doi.org/10.1016/j.pnpbp.2020.110016

Dvojković, A., et al. (2021) 'Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients', Progress in Neuro-Psychopharmacology and Biological Psychiatry, 105. doi: 10.1016/j.pnpbp.2020.110016

Dvojković A, Nikolac Perković M, Šagud M, Nedić Erjavec G, Mihaljević Peleš A, Švob Štrac D, and sur.. Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry [Internet]. 2021 March 08 [cited 2024 November 08];105. doi: 10.1016/j.pnpbp.2020.110016

A. Dvojković, et al., "Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients", Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 105, March 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:222295. [Accessed: 08 November 2024]

Metadata
Title (english)Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients
AuthorAnja Dvojković
AuthorMatea Nikolac Perković
AuthorMarina Šagud
AuthorGordana Nedić Erjavec
AuthorAlma Mihaljević Peleš
AuthorDubravka Švob Štrac
AuthorBjanka Vuksan Ćusa
AuthorLucija Tudor
AuthorZorana Kušević
AuthorMarcela Konjevod
AuthorMaja Živković
AuthorSaša Jevtović
AuthorNela Pivac
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Psychiatry and Psychological Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Psychiatry
Abstract (english)
Escitalopram and vortioxetine are efficacious antidepressants. They directly target serotonin (5-HT) system, but vortioxetine mechanism of action is distinct from the one of selective serotonin reuptake inhibitors (SSRIs). Treatment with SSRIs decrease platelet 5-HT concentration and increase peripheral brain-derived neurotrophic factor (BDNF) levels. Since vortioxetine has a multimodal mechanism of action, it is expected to have a greater effect on circulatory BDNF concentration, compared to conventional antidepressants. This longitudinal study aimed to explore and compare the effects of 4-weeks of treatment with vortioxetine and escitalopram on plasma BDNF and platelet 5-HT concentration in patients with major depressive disorder (MDD). The results revealed that vortioxetine significantly increased plasma BDNF concentration (p = .018) and significantly decreased platelet 5-HT concentration (p < .001). Treatment with escitalopram significantly decreased platelet 5-HT concentration (p < .001), but it did not affect plasma BDNF concentration (p = .379). Response to vortioxetine was not predicted by baseline plasma BDNF or platelet 5-HT concentration, but response to escitalopram was predicted by baseline platelet 5-HT concentration. These effects might be due to vortioxetine unique mechanism of action, but the clinical implications are unclear. It remains to be determined whether this finding extends during long-term vortioxetine treatment, and which, if any, clinical effects emerge from BDNF increase.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleProgress in Neuro-Psychopharmacology and Biological Psychiatry
Numberingvol. 105, 110016
p-ISSN0278-5846
e-ISSN1878-4216
DOIhttps://doi.org/10.1016/j.pnpbp.2020.110016
URN:NBNurn:nbn:hr:105:222295
Publication2021-03-08
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S0278584620303328
Type of resourceText
Access conditionsOpen access
Embargo expiration date: 2022-04-30
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2021-04-20 10:32:07